Needham analyst Michael Matson has maintained their bullish stance on LIVN stock, giving a Buy rating on October 31. Michael Matson has given ...

LONDON--LivaNova PLC announced Vladimir Makatsaria, CEO, will present a general business update during fireside chats at Stifel, Wolfe and Piper in New York.

LivaNova today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary endpoints.

In a report released today, Matt Miksic from Barclays assigned a Hold rating to LivaNova (LIVN – Research Report), with a price target of ...

Livanova said Monday a trial of its obstructive sleep apnea (OSA) implant met its primary safety and efficacy endpoints, positioning the company to seek approval once the analysis is complete. The ...

LivaNova has a 1-year low of $42.75 and a 1-year high of $64.47. The company has a market capitalization of $2.80 billion, a P/E ratio of 122.93 and a beta of 1.01.

LivaNova (LIVN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- ...

LivaNova (LIVN) closed the last trading session at $52.10, gaining 0% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street ...

LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.

LONDON - LivaNova PLC (NASDAQ:LIVN), a prominent medical technology company, today announced successful primary endpoint results for its OSPREY trial, which assesses the efficacy of the aura6000™ ...